Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • Author FAQs
    • Open access
    • COVID-19 submission information
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • Author FAQs
    • Open access
    • COVID-19 submission information
  • Alerts
  • Podcasts
  • Subscriptions

Bronchodilator reversibility in asthma and COPD: findings from three large population studies

Christer Janson, Andrei Malinovschi, Andre F.S. Amaral, Simone Accordini, Jean Bousquet, A. Sonia Buist, Giorgio Walter Canonica, Barbro Dahlén, Judith Garcia-Aymerich, Louisa Gnatiuc, Marek L Kowalski, Jaymini Patel, Wan Tan, Kjell Torén, Torsten Zuberbier, Peter Burney, Deborah Jarvis
European Respiratory Journal 2019 54: 1900561; DOI: 10.1183/13993003.00561-2019
Christer Janson
1Dept of Medical Sciences, Respiratory Allergy and Sleep Research, Uppsala University, Uppsala, Sweden
2Population Health and Occupational Disease, National Heart and Lung Institute, Imperial College London, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Christer Janson
  • For correspondence: christer.janson@medsci.uu.se
Andrei Malinovschi
3Dept of Medical Sciences, Clinical Physiology, Uppsala University, Uppsala, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andre F.S. Amaral
2Population Health and Occupational Disease, National Heart and Lung Institute, Imperial College London, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Andre F.S. Amaral
Simone Accordini
4Unit of Epidemiology and Medical Statistics, Dept of Diagnostics and Public Health, University of Verona, Verona, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jean Bousquet
5Fondation FMC VIA-LR, Montpellier, France
6Euforea, Brussels, Belgium
7Allergy Centre Charité, Dept of Dermatology and Allergy, Charité Universitätsmedizin Berlin, Berlin, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
A. Sonia Buist
8Pulmonary and Critical Care Medicine, Oregon Health and Science University, Portland, OR, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Giorgio Walter Canonica
9Personalized Medicine Clinic Asthma and Allergy Humanitas Research Hospital, Milan, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Barbro Dahlén
10Dept of Medicine, Unit for Heart and Lung disease, Karolinska Institutet, Stockholm, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Judith Garcia-Aymerich
11ISGlobal, Barcelona, Spain
12Universitat Pompeu Fabra (UPF), Barcelona, Spain
13CIBER Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Judith Garcia-Aymerich
Louisa Gnatiuc
14Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Dept of Population Health, University of Oxford, Oxford, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marek L Kowalski
15Dept of Immunology and Allergy, Medical University of Lodz, Lodz, Poland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jaymini Patel
2Population Health and Occupational Disease, National Heart and Lung Institute, Imperial College London, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wan Tan
16Centre for Heart Lung Innovation (Tan, Sin), University of British Columbia, St. Paul's Hospital Vancouver, Vancouver, BC, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kjell Torén
17Dept of Occupational and Environmental Medicine, University of Gothenburg, Gothenburg, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Torsten Zuberbier
7Allergy Centre Charité, Dept of Dermatology and Allergy, Charité Universitätsmedizin Berlin, Berlin, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter Burney
2Population Health and Occupational Disease, National Heart and Lung Institute, Imperial College London, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Deborah Jarvis
2Population Health and Occupational Disease, National Heart and Lung Institute, Imperial College London, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Bronchodilator response (BDR) testing is used as a diagnostic method in obstructive airway diseases. The aim of this investigation was to compare different methods for measuring BDR in participants with asthma and chronic obstructive pulmonary disease (COPD) and to study to the extent to which BDR was related to symptom burden and phenotypic characteristics.

Forced expiratory volume in 1 s (FEV1) and forced vital capacity (FVC) were measured before and 15 min after 200 μg of salbutamol in 35 628 subjects aged ≥16 years from three large international population studies. The subjects were categorised in three groups: current asthma (n=2833), COPD (n=1146) and no airway disease (n=31 649). Three definitions for flow-related reversibility (increase in FEV1) and three for volume-related reversibility (increase in FVC) were used.

The prevalence of bronchodilator reversibility expressed as increase FEV1 ≥12% and 200 mL was 17.3% and 18.4% in participants with asthma and COPD, respectively, while the corresponding prevalence was 5.1% in those with no airway disease. In asthma, bronchodilator reversibility was associated with wheeze (OR 1.36, 95% CI 1.04–1.79), atopy (OR 1.36, 95% CI 1.04–1.79) and higher exhaled nitric oxide fraction, while in COPD neither flow- nor volume-related bronchodilator reversibility was associated with symptom burden, exacerbations or health status after adjusting for pre-bronchodilator FEV1.

Bronchodilator reversibility was at least as common in participants with COPD as those with asthma. This indicates that measures of reversibility are of limited value for distinguishing asthma from COPD in population studies. However, in asthma, bronchodilator reversibility may be a phenotypic marker.

Abstract

Bronchodilator reversibility is at least as common in COPD as in asthma, indicating that measures of reversibility are of limited value for distinguishing asthma from COPD; however, bronchodilator reversibility in asthma may be a phenotypic marker. http://bit.ly/2W1oA4B

Footnotes

  • This article has supplementary material available from erj.ersjournals.com

  • Conflict of interest: C. Janson has nothing to disclose.

  • Conflict of interest: A. Malinovschi has nothing to disclose.

  • Conflict of interest: A.F.S. Amaral has nothing to disclose.

  • Conflict of interest: S. Accordini has nothing to disclose.

  • Conflict of interest: J. Bousquet reports personal fees and other funding from Chiesi, Cipla, Hikma, Menarini, Mundipharma, Mylan, Novartis, Sanofi-Aventis, Takeda, Teva and Uriach, and other funding from Kyomed, outside the submitted work.

  • Conflict of interest: S.A. Buist has nothing to disclose.

  • Conflict of interest: G.W. Canonica has nothing to disclose.

  • Conflict of interest: B. Dahlen has received personal fees from TEVA, Sanofi, GSK and AstraZeneca, outside the submitted work.

  • Conflict of interest: J. Garcia Aymerich has nothing to disclose.

  • Conflict of interest: L. Gnatiuc has nothing to disclose.

  • Conflict of interest: M.L. Kowalski has nothing to disclose.

  • Conflict of interest: J. Patel has nothing to disclose.

  • Conflict of interest: W. Tan has nothing to disclose.

  • Conflict of interest: K. Torén has nothing to disclose.

  • Conflict of interest: T. Zuberbier has received consultancy fees from Bayer Health Care, FAES, Novartis and Henkel; has received grants/has grants pensing form Novartis and Henkel, and has received lecture fees from AstraZeneca, AbbVie, ALK, Almirall, Astellas, Bayer HealthCare, Bencradm Berlin Chemie, FAES, HAL, Leti, Meda, Menarini, Merck, MSD, Novartis, Pfizer, Sanofi, Stallergenes, Takeda, TEVA, UCB, Henkel, Kryolan and L'Oreal, outside the submitted work.

  • Conflict of interest: P. Burney has nothing to disclose.

  • Conflict of interest: D. Jarvis has nothing to disclose.

  • Support statement: Funding was received from the European Union's Horizon 2020 research and innovation programme (no. 633212S), the Sixth European Union Framework Programme for Research (no. FOODCT_2004-506378), the Medical Research Council (grant number 92091), the Wellcome Trust (no. 085790/Z/08/Z) and the Swedish Heart and Lung Foundation (no. 20170303). For a more complete list of sponsors for the ECRHS and BOLD studies see www.ecrhs.org and www.boldstudy.org. Funding information for this article has been deposited with the Crossref Funder Registry.

  • Received March 20, 2019.
  • Accepted May 28, 2019.
  • Copyright ©ERS 2019
https://www.ersjournals.com/user-licence
View Full Text

ERS Members

myERS - ERS members : log in with your myERS username and password.

INDIVIDUALS

Log in Login as an individual user.

Forgot your username or password?

LIBRARY USERS

Log in through your institution

If your library has a subscription, you may already be logged in via your IP address. Otherwise you may be able to log in via one of the following routes.
You may be able to gain access using your login credentials for your institution. Contact your library if you do not have a username and password.
If your organization uses OpenAthens, you can log in using your OpenAthens username and password. To check if your institution is supported, please see this list. Contact your library for more details.
If you think you should have access, please contact your librarian or email journals@ersnet.org

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top
View this article with LENS
Vol 54 Issue 3 Table of Contents
European Respiratory Journal: 54 (3)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Bronchodilator reversibility in asthma and COPD: findings from three large population studies
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Alerts
Sign In to Email Alerts with your Email Address
Citation Tools
Bronchodilator reversibility in asthma and COPD: findings from three large population studies
Christer Janson, Andrei Malinovschi, Andre F.S. Amaral, Simone Accordini, Jean Bousquet, A. Sonia Buist, Giorgio Walter Canonica, Barbro Dahlén, Judith Garcia-Aymerich, Louisa Gnatiuc, Marek L Kowalski, Jaymini Patel, Wan Tan, Kjell Torén, Torsten Zuberbier, Peter Burney, Deborah Jarvis
European Respiratory Journal Sep 2019, 54 (3) 1900561; DOI: 10.1183/13993003.00561-2019

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Bronchodilator reversibility in asthma and COPD: findings from three large population studies
Christer Janson, Andrei Malinovschi, Andre F.S. Amaral, Simone Accordini, Jean Bousquet, A. Sonia Buist, Giorgio Walter Canonica, Barbro Dahlén, Judith Garcia-Aymerich, Louisa Gnatiuc, Marek L Kowalski, Jaymini Patel, Wan Tan, Kjell Torén, Torsten Zuberbier, Peter Burney, Deborah Jarvis
European Respiratory Journal Sep 2019, 54 (3) 1900561; DOI: 10.1183/13993003.00561-2019
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Abstract
    • Introduction
    • Methodology
    • Results
    • Discussion
    • Supplementary material
    • Shareable PDF
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Subjects

  • COPD and smoking
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

Original Articles

  • Allergen inhalation associated with airway dysfunction
  • OSTEOPOROSIS AND FACTURE RISK ASSOCIATED WITH ICS USE IN COPD
  • Cost-effectiveness of azithromycin in reducing asthma exacerbations
Show more Original Articles

COPD

  • OSTEOPOROSIS AND FACTURE RISK ASSOCIATED WITH ICS USE IN COPD
  • Should the number of acute exacerbations in the previous year be used to guide treatments in COPD?
  • Metered cryospray for patients with chronic bronchitis in COPD
Show more COPD

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • CME
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Submit a manuscript
  • ERS author centre

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2021 by the European Respiratory Society